Exposure to third trimester antenatal CMV viraemia was associated with lower neurodevelopmental scores at 24 months compared to unexposed children (adjusted difference -4.02 points; P=0.008).
Cohort (n=209)
Does antenatal exposure to CMV viraemia impair neurodevelopment in children at 24 months of age?
Antenatal exposure to CMV viraemia in the third trimester is associated with impaired neurodevelopment at 24 months of age, suggesting a potential target for antenatal intervention.
Effect estimate: adjusted difference -4.02 points (95% CI -7.01 to -1.04)
Absolute Event Rate: 91% vs 94.1%
p-value: p=0.008
Abstract We compared neurodevelopment at age 24-months among children born to mothers with or without CMV viraemia in the third trimester of pregnancy in rural Zimbabwe, using the Malawi Developmental Assessment Tool (MDAT) for gross motor, fine motor, language and social development. Among 209 children, 49 (23%) were exposed to third trimester CMV viraemia. The mean total MDAT score was 91.0 (SD 9.4) in CMV-exposed children versus 94.1 (8.8) in CMV-unexposed children (adjusted difference -4.02 points (95% confidence interval -7.01, -1.04, P=0.008). CMV exposure in utero, without evidence of congenital infection, may impair child neurodevelopment, providing a potential antenatal intervention target.
Evans et al. (Wed,) conducted a cohort in Antenatal CMV viraemia exposure (n=209). Antenatal CMV viraemia exposure (third trimester) vs. No CMV viraemia exposure was evaluated on Total Malawi Developmental Assessment Tool (MDAT) score at 24 months (adjusted difference -4.02 points, 95% CI -7.01 to -1.04, p=0.008). Exposure to third trimester antenatal CMV viraemia was associated with lower neurodevelopmental scores at 24 months compared to unexposed children (adjusted difference -4.02 points; P=0.008).